(Q36689152)

15 August 2017

1 reference

title

Immunotherapy of multiple myeloma: the start of a long and tortuous journey (English)

1 reference

15 August 2017

1 reference

1 reference

3

1 reference

15 August 2017

Simon J Harrison

1

1 reference

ORCID Public Data File 2021

author name string

Gordon Cook

series ordinal

2

1 reference

15 August 2017

H Miles Prince

series ordinal

4

1 reference

15 August 2017

publication date

1 December 2006

1 reference

Expert Review of Anticancer Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

6

1 reference

15 August 2017

issue

12

1 reference

15 August 2017

page(s)

1769-1785

1 reference

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Stem cell transplantation in multiple myeloma (0, 1, or 2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Bone marrow transplantation for multiple myeloma: where we are today

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Immune regulation in multiple myeloma: the host-tumour conflict

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Dendritic cells: specialized and regulated antigen processing machines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Prolongation of allograft survival in ccr7-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Role of CCR8 and other chemokine pathways in the migration of monocyte-derived dendritic cells to lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Inducible IL-2 production by dendritic cells revealed by global gene expression analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Dendritic cell lineage, plasticity and cross-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Dendritic cells as a tool to induce anergic and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Characterization of human blood dendritic cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Natural adjuvants: endogenous activators of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

111In-oxine and 99mTc-HMPAO labelling of antigen-loaded dendritic cells: in vivo imaging and influence on motility and actin content

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

A Toll-like receptor recognizes bacterial DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Evaluation of in vivo labelled dendritic cell migration in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Initial depletion of regulatory T cells: the missing solution to preserve the immune functions of T lymphocytes designed for cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Differential tumor surveillance by natural killer (NK) and NKT cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

In search of the 'missing self': MHC molecules and NK cell recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

NK cell compartments and their activation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Human natural killer cell function and their interactions with dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Anti-myeloma activity of natural killer lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Gammadelta T cells for immune therapy of patients with lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Rituximab administration following autologous stem cell transplantation for multiple myeloma is associated with severe IgM deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Characterization of clonogenic multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Making the most of mucin: a novel target for tumor immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Punish the parent not the progeny.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

An innate sense of danger

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Single step enrichment of blood dendritic cells by positive immunoselection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.12.1769

10.1586/14737140.6.12.1769

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference